Search

225 Result(s)
Sort by

Immuno-Oncology

Immuno-Oncology

We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
EURORDIS Award

EURORDIS Award

EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Partnership-with-clicktherapeutics

Partnership-with-clicktherapeutics

Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Partnering Vanderbilt WCNDD

Partnering Vanderbilt WCNDD

Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Supporting Fundappas

Supporting Fundappas

Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
Breaking prejudice in lung cancer

Breaking prejudice in lung cancer

At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
More Potential Overview

More Potential Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Their dogs are their world

Their dogs are their world

Corporate social responsibility in Brazil: Volunteer work and animal healthcare donations for homeless people and their pets.